NxStage Reports Record Fourth Quarter and Full-Year 2015 Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Piper Jaffray Cuts Price Target on Nxstage Medical (NXTM) Following Mixed 4Q Results
February 11, 2016 9:23 AM ESTPiper Jaffray maintained an Overweight rating on NxStage Medical (NASDAQ: NXTM), and cut the price target to $23.00 (from $24.00), following the company's 4Q earnings report. Revenue exceeded expectations, while net loss was in-line with Street estimates. 2016 revenue guidance was lower than Street estimates due to a $20M... More
Nxstage Medical (NXTM) Reports In-Line Q4 EPS; Issues Light FY16 Revenue Outlook
February 10, 2016 8:07 AM ESTNxstage Medical (NASDAQ: NXTM) reported Q4 EPS of ($0.04), in-line with the analyst estimate of ($0.04). Revenue for the quarter came in at $89.8 million versus the consensus estimate of $86.83 million.
GUIDANCE:
Nxstage Medical sees Q1 2016 revenue of $87-89 million, versus the consensus... More
